Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,995 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Disease; Dementia Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Healthy Patterns Sleep Study

NCT03682185
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder, Insomnia, Hypersomnia, Cognitive Impairment, Cognitive Decline, Mild Cognitive Impairment, Frontotemporal Dementia, Neurocognitive Disorders, Vascular Dementia, Sleep Disorder, Memory Impairment
Interventions
Attention-Control Condition, Timed Activity Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
421 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 30, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Results available

Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia

NCT05227820
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NE3107
Drug
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
55 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Oct 30, 2026, 12:08 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Juice Plus Supplement Clinical Trial

NCT04656860
View directory record Official record
Conditions
Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Juice Plus+
Dietary Supplement
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
55 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 30, 2026, 12:08 PM EDT
Recruiting Not applicable Interventional

The BRAIN App (Phase 2 SBIR)

NCT06298474
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Vascular Dementia
Interventions
The BRAIN App
Behavioral
Lead sponsor
Hopeful Aging
Industry
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Winchester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 12:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00605059
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[123I]AV94
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 30, 2026, 12:08 PM EDT
Completed Not applicable Interventional

Network Modulation in Alzheimer's Disease

NCT04045990
View directory record Official record
Conditions
Alzheimer Disease, Primary Progressive Aphasia, Mild Cognitive Impairment
Interventions
repetitive transcranial magnetic stimulation (rTMS)
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 30, 2026, 12:08 PM EDT
Active, not recruiting Not applicable Interventional

Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers

NCT05596760
View directory record Official record
Conditions
Dementia, Dementia, Vascular, Mixed Dementias, Alzheimer Disease, Huntington Disease, Lewy Body Disease, Creutzfeldt-Jakob Syndrome, Frontotemporal Lobar Degeneration, Cognitive Dysfunction, Cognitive Aging, Chronic Disease, Palliative Care, Patient Care, Health Care Quality, Access, and Evaluation, Patient Care, Health Communication, Patient Care Planning, Quality of Life
Interventions
Jumpstart Guide
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
1,802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 12:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep, Aging and Risk for Alzheimer's Disease

NCT01962779
View directory record Official record
Conditions
Sleep Disordered Breathing, Alzheimer's Disease
Interventions
Continuous positive airway pressure (CPAP)
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 30, 2026, 12:08 PM EDT
Completed Phase 4 Interventional Results available

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

NCT00948766
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
93
States / cities
Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 30, 2026, 12:08 PM EDT
Not listed No phase listed Observational

Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy

NCT03330353
View directory record Official record
Conditions
PSP - Progressive Supranuclear Palsy, PD - Parkinson's Disease, AD - Alzheimer's Disease, ALS (Amyotrophic Lateral Sclerosis)
Interventions
Pupillometry
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 30, 2026, 12:08 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT03131453
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CNP520 50mg, CNP520 15mg, Matching placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
1,145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
95
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 30, 2026, 12:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT01661673
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
EVP-0962, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
45 Years to 85 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 30, 2026, 12:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention

NCT02347202
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Online counseling via Zoom teleconferencing, Telephone support as needed
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 125 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 30, 2026, 12:08 PM EDT
Terminated Phase 2 Interventional

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

NCT01690195
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-126
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Long Beach, California • San Francisco, California • Hamden, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 30, 2026, 12:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Self-Care for Dementia Caregivers

NCT05309577
View directory record Official record
Conditions
Aging, Mental Disorder, Eating, Healthy, Physical Inactivity, Prodromal Symptoms, Sleep, Alzheimer Disease, Dementia, Circadian Rhythm Disorders
Interventions
Behavioral Self-Monitoring + Motivational Interviewing
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 30, 2026, 12:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ADRC Clinical Cohort (Alzheimer's Disease)

NCT06703541
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
25 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 12:08 PM EDT
Completed No phase listed Observational

Eye to Brain Connection

NCT05215782
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
Optina Diagnostics Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 30, 2026, 12:08 PM EDT
Completed Not applicable Interventional Results available

Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease

NCT03405662
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Vielight Neuro Gamma, Sham Vielight Neuro Gamma
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 30, 2026, 12:08 PM EDT
Completed Not applicable Interventional

Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia

NCT02675270
View directory record Official record
Conditions
Aphasia, Primary Progressive, Anomia, Alzheimer Disease
Interventions
Phonological, Orthographic, Semantic, Lexical, Untrained
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
40 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 30, 2026, 12:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

NCT07701161
View directory record Official record
Conditions
Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
Interventions
Not listed
Lead sponsor
Neurogen Biomarking LLC
Industry
Eligibility
40 Years to 90 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Dearborn, Michigan • Flint, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 30, 2026, 12:08 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

RQC for the Prevention of Alzheimer's Disease and Retinal Amyloid-β

NCT06470061
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
Interventions
Resveratrol, Quercetin, and Curcumin (RQC), Curcumin
Drug
Lead sponsor
Zaparackas and Knepper LTD
Other
Eligibility
50 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 30, 2026, 12:08 PM EDT
Completed No phase listed Observational

EEG/ERP Longitudinal Study in Alzheimer's Disease (AD)

NCT02769234
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ERP/EEG test, Psychometric testing
Procedure
Lead sponsor
Neuronetrix, Inc.
Industry
Eligibility
60 Years to 95 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
West Palm Beach, Florida • Brookline, Massachusetts • Bennington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 30, 2026, 12:08 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

NCT00663936
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T-817MA, Placebo
Drug
Lead sponsor
FUJIFILM Toyama Chemical Co., Ltd.
Industry
Eligibility
50 Years to 90 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 30, 2026, 12:08 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

NCT07094516
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VHB937, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
22
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 12:08 PM EDT